202 related articles for article (PubMed ID: 26693703)
21. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction.
Cooper JE; Gralla J; Klem P; Chan L; Wiseman AC
Transplantation; 2014 Jun; 97(12):1253-9. PubMed ID: 24937199
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
23. Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up.
Rabant M; Boullenger F; Gnemmi V; Pellé G; Glowacki F; Hertig A; Brocheriou I; Suberbielle C; Taupin JL; Anglicheau D; Legendre C; Duong Van Huyen JP; Buob D
Am J Transplant; 2018 Apr; 18(4):972-981. PubMed ID: 29206350
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
25. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
26. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
[TBL] [Abstract][Full Text] [Related]
28. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
[TBL] [Abstract][Full Text] [Related]
29. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
30. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
[TBL] [Abstract][Full Text] [Related]
31. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
[TBL] [Abstract][Full Text] [Related]
32. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
[TBL] [Abstract][Full Text] [Related]
33. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
[TBL] [Abstract][Full Text] [Related]
34. Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation.
Berger M; Lefaucheur C; Jordan SC
Transplantation; 2019 Sep; 103(9):1763-1775. PubMed ID: 30946220
[TBL] [Abstract][Full Text] [Related]
35. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.
Orandi BJ; Alachkar N; Kraus ES; Naqvi F; Lonze BE; Lees L; Van Arendonk KJ; Wickliffe C; Bagnasco SM; Zachary AA; Segev DL; Montgomery RA
Am J Transplant; 2016 Jan; 16(1):213-20. PubMed ID: 26317487
[TBL] [Abstract][Full Text] [Related]
36. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
37. Morphologic patterns and treatment of transplant glomerulopathy: A retrospective analysis.
Abreu R; Carvalho F; Viana H; Mesquita I; Possante M; Aires I; Caeiro F; Silva C; Cotovio P; Ferreira A; Remédio F; Nolasco F
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28135784
[TBL] [Abstract][Full Text] [Related]
38. De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.
Kiberd BA; Miller A; Martin S; Tennankore KK
Am J Transplant; 2016 Nov; 16(11):3212-3219. PubMed ID: 27106124
[TBL] [Abstract][Full Text] [Related]
39. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study.
Zhang H; Zheng C; Li X; Fu Q; Li J; Su Q; Zeng L; Liu Z; Wang J; Huang H; Xu B; Ye M; Liu L; Wang C
Front Immunol; 2020; 11():342. PubMed ID: 32184785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
